Should the Pharmacologic Management for Chronic Hepatitis C Encompass a Response Guided Therapy Treatment Plan?

Authors

Sarah Viscarra, University of North Dakota

Files

Document Type

Poster

Description

Pharmacologic advances have been made with the development of new drug therapies that essentially cure the hepatitis C virus, such as sofosbuvir. The purpose of this study is to determine whether sofosbuvir should encompass a response guided therapy treatment plan versus a standard treatment protocol, in efforts to limit the risk of adverse effects and to minimize the cost of treatment. The systematic review of literature retrieved from Pub Med and Cochrane, explored studies that compared a standard treatment protocol of 12 weeks, in male and female adults ages 18-90 years, to response guided therapy treatment plans based on each individual’s sustained virologic response. Reducing the duration of treatment will decrease the risk of adverse side effects, and lower the cost of therapy. This information will help practitioners guide appropriate length of HCV treatment based on each individual patient, to ensure a sustained viral load.

Department

Physician Assistant Studies

Degree Name

Master of Physician Assistant Studies (MPAS)

First Advisor

Vikki McCleary

Publication Date

2016

Keywords

Clinical Protocols; Hepatitis C -- drug therapy; Sofosbuvir -- therapeutic use; Comparative Study

Disciplines

Hepatology

Recommended Citation

Viscarra, Sarah, "Should the Pharmacologic Management for Chronic Hepatitis C Encompass a Response Guided Therapy Treatment Plan?" (2016). Physician Assistant Scholarly Project Posters. 89.
https://commons.und.edu/pas-grad-posters/89